drugset / Trial / NCT00768261

Corticolimbic Degeneration and Treatment of Dementia

NCT00768261

RandomizedParallel-groupOpen-labelTreatment

Summary

The overall purpose of this research is to determine if there is a relationship between your symptoms of Dementia of the Alzheimers type and changes in the size and shape of certain brain structures during combined Donepezil (Aricept®) and Memantine (Namenda®) treatment.

Timeline

Start
2004-11
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 10 mg
Comparator Memantine Unknown 20 mg

Indications